Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive malignancy with poor prognosis, in part because of the current lack of any approved molecularly targeted therapy. We evaluated various combinations of three different drugs: nintedanib, an antiangiogenic TKI targeting VEGF receptors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Reguera-Nuñez, Elaine, Xu, Ping, Chow, Annabelle, Man, Shan, Hilberg, Frank, Kerbel, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330500/
https://www.ncbi.nlm.nih.gov/pubmed/30635009
http://dx.doi.org/10.1186/s13046-018-0999-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330500/
https://www.ncbi.nlm.nih.gov/pubmed/30635009
http://dx.doi.org/10.1186/s13046-018-0999-5

Ejemplares similares